NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

CompletedN/A

Sponsor: AstraZeneca

Conditions: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Countries: Japan

To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Patients with previously untreated chronic lymphocytic leukaemia (including small lymphocytic lymphoma) who are treated with Calquence for the first time will be enrolled in the study after the approval date of the sJNDA for the additional indication.

\-

Exclusion Criteria:

None

\-

Locations (15)

Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Hyōgo, Japan
Kanagawa, Japan
Kyoto, Japan
Miyazaki, Japan
Nagano, Japan
Nara, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shizuoka, Japan
Tokyo, Japan
Yamanashi, Japan